Peptide Therapeutics Market By Type (Branded Peptide and Generic Peptide), By Application (Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease, and Others), By Route of Administration (Oral Administration, Parenteral Administration and Others) and By Region - Trends, Analysis and Forecast till 2030

Peptide Therapeutics Market size accounted for USD 36.76 Billion in 2020 and is estimated to be USD 66.18 Billion by 2030 and is anticipated to register a CAGR of 6.10%.

Peptide therapeutics is extensively used in cancer treatment, followed by infectious treatment medications in metabolic disorders, infectious disease, and diabetes, among others. The joining of two or more amino acid monomers via amide bonds forms peptides. The size of a peptide is what separates it from a protein. Peptides are defined as compounds that include no more than 50 amino acids. Peptides work by attaching to particular cell surface receptors, acting as mimics of receptor ligands, and assisting on the cell membrane to treat disorders. Peptide therapeutics, due to their increased specificity, safety, tolerability and its ability to offer better efficiency results in various therapeutic treatments, are in greater demand.  Increasing incidence and prevalence cases of cancer and diabetes, combing with growing research and development (R&D) activities to develop novel treatment therapies based on peptide therapeutics in the market, is expected to show lucrative growth in near future. 

                    For More Report Details, Download Free Sample PDF

Companies invest much in R&D

Due to the measures done by numerous firms to investigate the creation of novel medication candidates, the market is anticipated to experience profitable growth throughout the forecast period. Companies invest much in R&D to create novel pharmaceuticals that are more effective at treating the ailments they are targeting in order to maintain their position in the market. Over the past ten years, there have been a lot more clinical trials for these medications. Over the projection term, this is also anticipated to fuel growth. For instance, Amgen and Generate Biomedicines announced a research partnership agreement in January 2022 to investigate and develop protein therapies for its five clinical objectives across numerous therapeutic areas and delivery methods.

Additionally, according to the World Health Organization, chronic diseases including cancer, diabetes, and cardiovascular diseases are the main causes of morbidity and mortality worldwide (WHO).

lchronic disease rates have exploded, spreading across all regions and affecting people from all socioeconomic backgrounds. According to estimates, chronic diseases will account for 70% of all fatalities and 60% of the burden of disease worldwide in 2020. As a result, the market is expected to be driven by the rising prevalence of chronic diseases and the increased demand for efficient therapies. However, the market expansion is anticipated to be constrained by the uncertainty surrounding peptide therapies, the rising cost of drug development, and tight regulatory requirements for medication approval.

Peptide therapeutics market has been segmented on the basis of type, application, route of administration and region.

Type Insights

On the basis of type, the peptide therapeutics market is segmented into branded peptide therapeutics and generic peptide therapeutics.  

Application Insights

On the basis of application, the peptide therapeutics market is segmented into cancer, cardiovascular disease, metabolic disease, respiratory disease, infectious disease and others.

Route of Administration Insights

On the basis of Route of administration for peptide therapeutics market includes oral administration, parenteral administration and others.

Regional Insights:

On region the Peptide Therapeutics Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America expected to hold major market share in peptide therapeutics market, owing to the increasing demand of peptide therapeutics in cancer and diabetes treatment medications in these region, and increasing engagement of key manufacturing players and government in research and development for peptide therapeutics.  The growing need for peptide therapies treatment methods, increased medical research and development, and other factors are anticipated to boost the markets for these products in Western and Eastern Europe. The market for peptide therapies in Latin America is anticipated to increase steadily. The market for peptide therapies in Asia Pacific is expected to grow at a rapid CAGR throughout the forecast period, making it a very promising market. This is brought on by a sizable patient base, rising healthcare costs, and a growing demand for novel and cutting-edge therapies. Compared to other regions, the MEA peptide therapeutics market is anticipated to grow a little more slowly, but it is anticipated to accelerate toward the end of the forecast period.

Report Scope:

Recent Development:

• The developer of NURTEC ODT, an advanced dual-acting migraine medicine approved for both acute treatments and episodic migraine prevention in adults, Biohaven Pharmaceutical Holding Company Ltd. and Pfizer Inc. announced a new collaboration in May 2022.
• Bristol Myers Squibb and LOTTE Corporation announced in MAY 2022 that LOTTE had made the decision to purchase Bristol Myers Squibb's production facility in East Syracuse, New York. LOTTE's innovative biologics CDMO business in the United States will be housed in East Syracuse.

Peptide Therapeutics Market, By Region:

• North America
  • Canada
  • U.S.
  • Europe
    • Germany
    • UK
    • France
    • Russia
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • Israel
    • South Africa
    • Rest of Middle East & Africa

The leading players operating in the Peptide Therapeutics Market includes

• Sanofi S.A. is a French-based international healthcare corporation with its headquarters in Paris.
• Pfizer Inc. is a worldwide pharmaceutical and biotechnology company with its main office in Manhattan, New York City.
• AstraZeneca Plc is a worldwide pharmaceutical and biotechnology firm with British and Swedish roots. Its headquarters are located in England.
• GlaxoSmithKline Plc a British multinational pharmaceutical corporation with its headquarters in London, formerly known as GlaxoSmithKline plc.
• Abbott Laboratories is a worldwide American firm that manufactures medical equipment and provides healthcare, with its headquarters in Abbott Park, Illinois.
• Novartis AG is a Swiss-based healthcare organisation that offers solutions to meet the changing demands of patients around the world.
• Teva Pharmaceutical Limited is a large, international pharmaceutical firm based in Petah Tikva, Israel.
• F. Hoffmann-La Roche AG a multinational healthcare corporation based in Switzerland, Roche is more popularly known. It has two business segments: pharmaceuticals and diagnostics. Shares of Roche Holding AG, its holding company, are traded on the SIX Swiss Exchange.
• Eli Lilly and Company is a multinational American pharmaceutical corporation with its headquarters in Indianapolis, Indiana.
• Johnson & Johnson is an American firm established in 1886 that creates consumer packaged goods, pharmaceuticals, and medical equipment.